Last reviewed · How we verify
US-STELARA®
At a glance
| Generic name | US-STELARA® |
|---|---|
| Also known as | STELARA® (ustekinumab) |
| Sponsor | BioFactura Australia Pty Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetics, Safety and Tolerability Study of AVT04 to EU Approved and US Licensed Stelara (Ustekinumab) (PHASE1)
- A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to European Union (EU) Sourced Stelara and United States of America (US) Sourced Stelara in Healthy Subjects (PHASE1)
- Bioequivalence Phase I Study of BFI-751 Compared With EU and US-STELARA® in Healthy Adults (PHASE1)
- Comparative Study to Evaluate the Pharmacokinetics of BAT2206 vs Stelara® in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- US-STELARA® CI brief — competitive landscape report
- US-STELARA® updates RSS · CI watch RSS
- BioFactura Australia Pty Ltd. portfolio CI